4.7 Review

Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats

Journal

CANCER
Volume 124, Issue 24, Pages 4633-4649

Publisher

WILEY
DOI: 10.1002/cncr.31630

Keywords

artificial intelligence; deep learning; habitat imaging; image analytics; machine learning; radiomics

Categories

Funding

  1. National Institutes of Health [R01CA187532, U01CA143062, U01CA187947, R01CA160251, U24CA194354, U01CA190234]

Ask authors/readers for more resources

Although cancer often is referred to as a disease of the genes, it is indisputable that the (epi)genetic properties of individual cancer cells are highly variable, even within the same tumor. Hence, preexisting resistant clones will emerge and proliferate after therapeutic selection that targets sensitive clones. Herein, the authors propose that quantitative image analytics, known as radiomics, can be used to quantify and characterize this heterogeneity. Virtually every patient with cancer is imaged radiologically. Radiomics is predicated on the beliefs that these images reflect underlying pathophysiologies, and that they can be converted into mineable data for improved diagnosis, prognosis, prediction, and therapy monitoring. In the last decade, the radiomics of cancer has grown from a few laboratories to a worldwide enterprise. During this growth, radiomics has established a convention, wherein a large set of annotated image features (1-2000 features) are extracted from segmented regions of interest and used to build classifier models to separate individual patients into their appropriate class (eg, indolent vs aggressive disease). An extension of this conventional radiomics is the application of deep learning, wherein convolutional neural networks can be used to detect the most informative regions and features without human intervention. A further extension of radiomics involves automatically segmenting informative subregions (habitats) within tumors, which can be linked to underlying tumor pathophysiology. The goal of the radiomics enterprise is to provide informed decision support for the practice of precision oncology. Cancer 2018;124:4633-4649. (C) 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available